AddedRisk Factors
Additionally, on November 3, 2025, we announced topline results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of VYONDYS 53 and AMONDYS 45, which primary endpoint did not meet statistical significance. Our analysis of the trial results is ongoing. However, these topline results could lead to regulatory actions from the FDA, including changes to our drug labels or revocation of accelerated approvals and directives to remove these products from the market altogether, negatively impact patient demand for these products or result in changes to reimbursement and coverage of these products by payors. Such outcomes could adversely impact our business, financial condition, results of operations, financial guidance, ability to accurately forecast key financial metrics, and prospects.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedRisk Factors
•an inability to retain an adequate number of effective commercial personnel. For example, a number of commercial personnel have departed from the Company in connection with and following our Restructuring, which has resulted in the need for additional hiring and training efforts, which may continue in the future;
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedRisk Factors
In the siRNA field, we face competition by third parties who are also developing product candidates targeting the same disease states as our product candidates, including but not limited to Avidity (DM1, FSHD), Dyne (DM1, FSHD), Arthex Biotech (DM1), PepGen (DM1), Vertex Pharmaceuticals (DM1), Entrada (FSHD), Celularity (FSHD), Novartis (FSHD), Biohaven (SCA), Vico Therapeutics (SCA, Huntington’s), Skyhawk Therapeutics (SCA, Huntington’s), uniQure (Huntington’s), Roche Ionis (Huntington’s), Wave (Huntington’s), and PTC (Huntington’s). Some, but not all, of these entities’ product candidates use RNA technologies. Several of these companies’ product candidates are further along in development and may obtain regulatory approval in advance of our product candidates. These and other competitors may have greater financial, scientific, and commercial resources than us, which may impact our ability to secure the technologies we desire or to otherwise effectively compete in these disease states.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedRisk Factors
Further, any reduction in the FDA’s workforce could delay or materially impact the FDA’s feedback on our development programs, including through meetings and other informal interactions, and affect the FDA’s review and oversight of our product candidates. Additionally, changes in the FDA personnel under the new presidential administration may lead to changes in the regulations, policies and operations of the FDA, which may impact our clinical development plans. Any of these actions could adversely affect the development and approval of our product candidates. In addition, as a result of any government shutdown, the FDA staff may be unable to process and review regulatory submissions in a timely manner or at all.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RemovedRisk Factors
•the exercise by Roche of its option to obtain an exclusive license to commercialize one or more of our Duchenne products beyond ELEVIDYS outside of the U.S. and Roche’s subsequent commercialization efforts.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•challenges to the pricing of drugs or limits or prohibitions on reimbursement for specific products through other means;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, we have granted Roche an exclusive option to obtain an exclusive license to commercialize certain products, including eteplirsen, golodirsen and casimersen, outside of the U.S. If this option is exercised, Roche will have sole control over and decision-making authority with respect to the commercialization of such products outside the U.S.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
on how the Catalyst decision is ultimately implemented. Legislation has been introduced to amend the Orphan Drug Act in a way that may prevent these effects of the Catalyst decision, but it is unclear if or when such legislation could be enacted.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
track and breakthrough therapy designations, including early interactions with the FDA, but the exact mechanisms have not yet been announced by the FDA.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We also rely on a third party to design, manufacture, obtain and maintain regulatory approval for necessary diagnostic tests for ELEVIDYS. Any delay or failure by us or our collaborators to develop or obtain regulatory approval of the necessary diagnostic tests could harm our business, possibly materially.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The operations at one of our partner sites could also be disturbed by man-made or natural disasters, public health pandemics or epidemics or other business interrupts such as potential supply chain disruptions caused by the ongoing conflict between Russia and Ukraine. In addition, the need to prioritize rated orders issued by the Federal Emergency Management Agency pursuant to the U.S. Defense Production Act could impact the manufacturing, supply chain and distribution of our products and product candidates.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We currently have development, manufacturing and testing agreements with third parties to manufacture supplies of ELEVIDYS and our gene therapy product candidates. Several factors could cause production interruptions, including talent acquisition/retention, equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of suppliers.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, the FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the competent authority authorizes its release.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing process which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
obligated to expend time, money and effort in production, record keeping and quality control to seek to assure that the product meets applicable specifications and other requirements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, we cannot predict to what extent an economic recession, changes in fiscal policy policy, restrictions in eligibility for or reductions in funding government health care programs such as Medicaid or a general increase in unemployment rates may disrupt global healthcare systems and access to our products or result in a widespread loss of individual health insurance coverage due to unemployment or trends in employee attrition, a shift from commercial payor coverage to government payor coverage, coverage may disrupt access to our products or result in an increase in demand for patient assistance and/or free drug programs, any of which would adversely affect access to our products and our net sales.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid and private insurance healthcare costs, including proposed or implemented reforms involving price controls, waivers from Medicaid drug rebate law requirements, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs and implementing new requirements for, or eliminating caps on, rebates paid on products under government healthcare programs. reforms.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
While orphan status for any of our products, if granted or maintained, would provide market exclusivity in the U.S. for seven years from the time periods specified above upon approval, of approval of the applicable market authorization, we would not be able to exclude other companies from obtaining regulatory approval of products using the same or similar active ingredient for the same indication during or beyond the exclusivity period applicable to our product on the basis of orphan drug status (e.g., seven years in the U.S.).
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, we are aware of many pharmaceutical and biotechnology companies that are actively engaged in research and development using platform technologies that may be viewed as competing with ours beyond and including those companies mentioned immediately above, such as Alnylam Pharmaceuticals, Inc., Arbutus (formerly Tekmira Pharmaceuticals Corp.), Deciphera Pharmaceuticals, Ionis Pharmaceuticals, Inc., Roche Innovation Center Copenhagen (formerly Santaris Pharma A/S), Shire plc (now Takeda), Biogen, Moderna Therapeutics, Avidity, Dyne Therapeutics, Stoke Therapeutics, Ultragenyx, Sanofi and PepGen. Inc.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Lack of efficacy and/or serious adverse events related to clinical trials or our commercial products we, our strategic partners or other companies conduct, even if such adverse events are not ultimately attributable to the relevant product candidates or products, and/or failed commercialization of gene therapy products may result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates, all of which could adversely impact our business.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
The US Even though, the supply of healthcare related products have generally been exempted from global sanctions in the past, the U.S. and other nations have raised the possibility of sanctions on companies that do business with Russia or its allies, including Belarus. Belarus, including healthcare companies.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, as of December 31, 2024, 2025, there were approximately 3.4 1.8 million shares of common stock available for future issuance under our 2018 Equity Incentive Plan, approximately 0.2 million shares of common stock available for issuance under our Amended and Restated 2013 Employee Stock Purchase Plan, and approximately 1.0 2.3 million shares of common stock available for issuance under our 2024 Employment Commencement Incentive Plan.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, we will have limited influence and control over the development and commercialization activities of Roche in the territories in which it leads development and commercialization of ELEVIDYS, and if the exclusive option is exercised, in the territories in which it may lead commercialization of certain other products or product candidates. ELEVIDYS.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Over the last few years, we have had several executive management changes. changes, including the departure of Dallan Murray, Chief Customer Officer in July 2025 and Bilal Arif, Chief Technical Operations Officer in August 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our stock has had significant swings in trading prices, in particular in connection with our public communications regarding feedback received from regulatory authorities. authorities, the adverse events observed in non-ambulatory patients receiving ELEVIDYS and in our Phase 1/2 LGMD trial for SRP-9004, and our ESSENCE readout.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
RMAT designations will accelerate approval and will include all the benefits of fast track and breakthrough therapy designations, including early interactions with the FDA, but the exact mechanisms have not yet been announced by the FDA.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
(i) exon skipping product candidates, such as Wave (targeting various exons, including 53 and 51), Nippon Shinyaku (targeting various exons, including 51 and 45, and notably for exon 53 for which it has received accelerated FDA approval for its product Viltepso (viltolarsen)), Dyne Therapeutics pursuing antibody-oligonucleotide conjugates for exons 44, 45, 51, and 53, Avidity Biosciences pursuing antibody-oligonucleotide conjugates for exons 44, 45 and 51, PepGen (notably for exon 51), SQY Therapeutics and BioMarin (BMN-351 (for exon 51), Entrada (notably for exon 51), Entrada; 44, 45, 50, and 51);
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Failure to comply with healthcare and other regulations is may subject us to substantial penalties and our business, operations and financial condition could be adversely affected.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
Revenues from product sales are recorded at the time of sale at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, governmental chargebacks including PHS chargebacks, prompt pay discounts, patient assistance programs and distribution fees. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if no payments are required of us) or a current liability (if a payment is required of us). Our estimates take into consideration current contractual and statutory requirements. Actual amounts of consideration ultimately received or paid may differ from our estimates.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
For 2025, we recognized $175.5 million in collaboration revenue consisting of (1) $112.0 million related to the expiration of an option for a certain program previously recorded as deferred revenue and (2) $63.5 million related to milestone payments received under the Roche Collaboration Agreement from the regulatory approval of ELEVIDYS in Japan for individuals ages 3- to less than 8-years-old, who do not have any deletions in exon 8 and/or exon 9 in the Duchenne gene and who are negative for anti-AAVrh74 antibodies, as compared to $48.0 million in collaboration revenue in 2024 related to Roche’s declined option to acquire the ex-US rights to a certain external, early-stage Duchenne development program previously recorded as deferred revenue. Please refer to Note 3, License and Collaboration Agreements for further discussion of the Roche Collaboration Agreement.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
While the Roche Supply Agreement is in the process of being negotiated, we delivered batches of commercial ELEVIDYS supply to Roche that were agreed upon on a purchase order-by-purchase order basis. Contract manufacturing revenue increased by $75.0 million primarily due to increased deliveries of ELEVIDYS to Roche in 2025 and increases in our manufacturing costs driven by greater-than-expected write-offs of (1) batches of our products not meeting our quality specifications as well as (2) certain excess or obsolete inventory attributable to Roche during 2025. In addition, royalty revenue increased by $17.4 million from increased sales of ELEVIDYS by Roche outside of the U.S. in 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The Restructuring, announced in July 2025, was designed to reduce operating expenses and align our cost structure with strategic priorities, aiming to enhance financial flexibility and meet our 2027 financial obligations. This plan included a revised cost structure, program portfolio and a reduction in force. The workforce reduction represented approximately 36% of our workforce. We recorded a restructuring charge of $42.0 million for 2025, primarily related to employee termination benefits, including severance, along with accelerated depreciation for assets impacted by the restructuring plan, with no similar activity in 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
Please refer to Note 4, Restructuring for additional information on the Restructuring.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On August 28, 2025 (the "First Effective Date"), we completed a partial refinancing of the 2027 Notes (the "August 2025 Exchange") and exchanged $700.0 million in aggregate principal amount of 2027 Notes for the following consideration:
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
(2)cash payments of $127.3 million, including $4.0 million of accrued interest of the 2027 Notes; and
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
(3)5.9 million shares of our common stock with a fair market value of approximately $104.9 million, net of issuance costs of $2.4 million.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On December 18, 2025 (the "Second Effective Date"), we completed the second partial refinancing of the 2027 Notes (the “December 2025 Exchange”) and exchanged $291.4 million in aggregate principal amount of the 2027 Notes for the following consideration:
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
(2)cash payments of $31.6 million, including $1.0 million of accrued interest of the 2027 Notes.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The Company concluded that neither the August 2025 Exchange nor December 2025 Exchange (collectively, the “Exchange Transactions”) met the criteria for induced conversion. Further, we concluded that the refinanced debt in the August 2025 Exchange as well as approximately $182.8 million of that in the December 2025 Exchange were substantially different from the original debt and, thus, accounted for as debt extinguishments. The gain recognized on the extinguishments for the year ended December 31, 2025 was $16.9 million. The Company also determined that the remaining $108.6 million of the refinanced debt in the December 2025 Exchange was not substantially different from the original debt and, therefore, accounted for as debt modification. Please refer to Note 13, Indebtedness for additional information on the August 2025 Exchange and December 2025 Exchange.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
In the August 2025 Exchange, we exchanged 2027 Notes for a combination of 2030 Notes, common stock and cash. Concurrently with the issuance of the 2030 Notes during the August 2025 Exchange, we completed the private placement of approximately 1.1 million shares of Common Stock to J. Wood Capital Advisors LLC ("JWCA") at a purchase price per share of $18.07. In the December 2025 Exchange, we exchanged 2027 Notes for 2030 Notes and cash. While the 2030 Notes carry a higher interest rate than the 2027 Notes, the August 2025 Exchange and December 2025 Exchange reduced our total outstanding principal amount of long-term debt by $98.0 million and delayed $893.4 million of the principal payment to 2030. Additionally, our Revolving Credit Facility remains undrawn as of December 31, 2025. Refer to Note 13, Indebtedness for additional discussion of our outstanding indebtedness. We periodically engage in discussions with the lenders under our Revolving Credit Facility regarding business developments and our continued ability to borrow under our Revolving Credit Facility. See Risk Factors—Risks Related to our Financial Condition and Capital Requirements—Our existing and any future indebtedness could adversely affect our ability to operate our business.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RemovedMD&A
oEXONDYS 51 (eteplirsen) Injection (“EXONDYS 51”), granted accelerated approval by the FDA on September 19, 2016, is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping. EXONDYS 51 uses our PMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
oVYONDYS 53 (golodirsen) Injection (“VYONDYS 53”), granted accelerated approval by the FDA on December 12, 2019, is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. VYONDYS 53 uses our PMO chemistry and exon-skipping technology to skip exon 53 of the dystrophin gene.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
oAMONDYS 45 (casimersen) Injection (“AMONDYS 45”), granted accelerated approval by the FDA on February 25, 2021, is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. AMONDYS 45 uses our PMO chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an AAV-based gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is also approved for non-ambulatory patients under the accelerated approval pathway. ELEVIDYS was previously granted accelerated approval by the FDA on June 22, 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
A summary description of our key product candidates, including those in collaboration with our strategic partners, is as follows:
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•SRP-9003 (LGMD, gene therapy program). We are developing gene therapy programs for various forms of LGMD. The most advanced of our LGMD product candidates, SRP-9003, aims to treat LGMD2E, also known as beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss, inflammation and muscle fiber replacement with fat and fibrotic tissue. SRP-9003 is designed to transfect a gene that codes for and restores beta-sarcoglycan protein with the goal of restoring the dystrophin associated protein complex. SRP-9003 has generated positive pre-clinical safety and efficacy data utilizing the AAVrh.74 vector, the same vector used in our SRP-9001 gene therapy program. A Phase 1/2a trial of SRP-9003 commenced in the fourth quarter of 2018. In June 2020, we announced safety and expression results from three clinical trial participants in the high-dose cohort measured at 60 days, and one-year functional data from three clinical trial participants in the low-dose cohort. In March 2022, we announced 36-month functional data from three clinical trial participants in the low-dose cohort and 24-month functional data from two clinical trial participants in the high-dose cohort. In December 2024, we announced that we had completed enrollment and dosing in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec).
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
inventory, obsolete inventory, or inventories that do not meet our quality specifications is recorded as a component of cost of sales in the consolidated statements of comprehensive income (loss).
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
For the Year Ended December 31, 2024 2023 Change Change (in thousands) $ % Contract manufacturing $ 49,038 $ 9,216 $ 39,822 NM* Amortization of performance obligations** 48,000 89,244 (41,244) (46 Royalty revenue 16,981 — 16,981 NM* Total collaboration and other $ 114,019 $ 98,460 $ 15,559 16
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
** Related to the recognition of previously deferred revenue under the Roche collaboration agreement as the Company satisfies its performance obligations under the contract. For more information, please read Note 3, License and Collaboration Agreements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
For the Year Ended December 31, 2024 2023 Change Change (in thousands) $ % Inventory costs related to products sold (excluding products sold to Roche**) $ 249,108 $ 108,988 $ 140,120 129% Royalty payments 47,744 39,537 8,207 21% Inventory costs related to products sold to Roche** 22,247 1,818 20,429 NM* Total cost of sales (excluding amortization of in-licensed rights) $ 319,099 $ 150,343 $ 168,756 112%
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
*Beginning in 2024, we implemented an updated manufacturing absorption methodology that allocates the absorption of indirect manufacturing costs to their respective originating categories. Research and development expenses by category, specifically, manufacturing expenses, compensation and other personnel expenses, facility- and technology-related expenses and professional services, have been reclassified for 2023 for comparability. This reallocation has no impact on the total research and development expenses recognized.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•$10.3 million increase in stock-based compensation expense primarily related to the achievement of performance conditions related to certain PSUs during the year ended December 31, 2024 and changes in headcount;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
The increase change primarily reflects an increase in net product revenues of ELEVIDYS of $620.4 $77.9 million in 2024 2025 as a result of its initial FDA approval in June 2023 and subsequent expanded label approval in June 2024. 2024, partially offset by higher discounts associated with the PHS chargeback program in 2025 due to ELEVIDYS no longer qualifying for pediatric designation, which had previously reduced our rebate obligations to certain payers.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024 and 2023, 2024, our principal sources of liquidity were primarily derived from the sales of our products, net the maturity and sale of available-for-sale securities, our collaboration arrangement with Roche, proceeds from sale exercise of the ELEVIDYS PRV, proceeds from stock options and the settlement of capped call options associated with the 2024 Notes (the “2017 Capped Calls”) and our collaboration arrangement with Roche. convertible senior notes due on November 15, 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
While our contractual obligations, commitments and debt service requirements over the next several years are significant, we intend to continue to fund our short-term financing needs and working capital requirements from cash flows of operating activities as well as cash on hand and such Such sources are anticipated to be adequate to fund working capital requirements for at least twelve months from the date these consolidated financial statements were issued.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
While our contractual obligations, commitments and debt service requirements over the next several years are significant, we intend to continue to fund our short-term financing needs and working capital requirements from cash flows of from operating activities as well as cash on hand and such sources are anticipated to be adequate to fund working capital requirements for at least twelve months drawing from the date these consolidated financial statements were issued. our Revolving Credit Facility, as needed.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Applying our proprietary, highly differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne, LGMDs, Duchenne and LGMD, as well as those through our partnered programs with Arrowhead, including FSHD, DM1, SCA2, IPF, Huntington's disease and other neuromuscular and central nervous system related disorders. skeletal diseases.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The changes in our working capital for both periods primarily reflect the use of cash in operating activities, as well as an increase a reduction in inventory due our cash, cash equivalents and investments to fund the capitalization of ELEVIDYS inventory after its approval Arrowhead Payments in June 2023. 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Additional information regarding our obligations under debt, lease, and manufacturing arrangements is provided in Note 13, Indebtedness, Note 19, Leases, Note 22, Commitments and Contingencies Leases and Note 23, Subsequent event, Commitments and Contingencies, respectively, to the consolidated financial statements. statements included elsewhere in this Annual Report on Form 10-K.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Our pipeline includes programs in various stages of pre-clinical and clinical development, reflecting reflects our aspiration to apply our multifaceted approach and expertise in precision genetic medicine to make a profound difference in the lives of patients suffering from rare diseases.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
This was partially offset by a decrease an increase in clinical supply costs due to timing for our additional SRP-9001 gene therapy programs. clinical batches released in 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
We periodically analyze our inventories for excess amounts or obsolescence and write down excess or obsolete or otherwise unmarketable inventory to its estimated net realizable value based on assumptions about expected future demand and market conditions. value.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Our principal uses of cash are for 2024 were inventory commitments, research and development expenses, manufacturing costs, selling, general and administrative expenses, investments, capital expenditures, business development transactions, settlement of long-term debt expenditures and other working capital requirements.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
We believe that our existing cash, cash equivalents and cash equivalents, investments along with future cash generated from operations and availability under our Revolving Credit Facility will be sufficient to meet the capital requirements of our operations for the next 12 twelve months and foreseeable future.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new